Signals
When a Cardiology Trial ‘Wins’, What Actually Improved?
Cardiovascular trials are increasingly using hierarchical composite endpoints to capture treatment effects across survival, hospitalisation, symptoms and quality of life. The approach can reflect clinical priorities more effectively than conventional time-to-first-event analysis, but a positive win ratio does not necessarily mean fewer deaths or cardiovascular events.
Physical activity continues to strengthen its case as a cross-disease prevention strategy
The Air We Breathe May Be Shaping the Future Burden of Blindness
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
AI Pathology Starts Moving Toward Treatment Selection
Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis
A Urine Test for Alzheimer’s Would Change the Access Conversation
AI Multiomics Moves Into the Trial Stratification Layer
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.